In the end, poziotinib in the ZENITH20 clinical trial (NCT03318939) demonstrated antitumor activity with a durable response and manageable safety profile as the second-generation TKI in previously treated NSCLC patients with HER2 exon 20 insertions [77,78,79]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.